---
document_datetime: 2026-01-15 10:14:57
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vyvgart-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vyvgart-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9958825
conversion_datetime: 2026-01-17 13:31:51.221714
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vyvgart

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.c.2 Change in test procedure for an | 19/12/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000314222                     | excipient - B.II.c.2.d Other changes to a test procedure (including replacement or addition) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000291882 | This was an application for a group of variations. B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.d Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.b.2 Change to importer, batch release | 11/12/2025 | SmPC, Annex II, Labelling and PL | In view of the data submitted with the variation, amendments to Annex(es)I, II, IIIA, IIIB and to the Risk Management Plan are recommended. The SmPC (Vyvgart 20 mg/mL concentrate for solution for infusion) section 6.1 has been updated to reflect the new composition i.e. replacement of the excipients: Sodium dihydrogen phosphate, monohydrate and Disodium hydrogen phosphate, anhydrous With: L-histidine, L-histidine hydrochloride monohydrate, L-methionine and Sucrose and to provide further precision to the description of the excipient L-arginine hydrochloride. For full list of excipients see section 6.1 of the SmPC. Changes to sections 2, 3 and 4 are also made as a result of the change in composition and pH change. Annex II has been updated to delete: 1) Lonza Biologics plc (Slough), 228 Bath Road, Slough, Berkshire, SL1 4DX UK as a site responsible for manufacture of the active substance. 2) ProPharma Group The Netherlands B.V., Bio Science Park, Schipholweg 73, 2316 ZL Leiden, Netherlands, as a site responsible for batch release of the finished product. The Labelling and PL have been updated accordingly (both amended to reflect the new composition and the ProPharma Group site deleted from the PL). |

<div style=\"page-break-after: always\"></div>

|                                       | the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.c The product is a biological/immunological medicinal product and the change requires an assessment of comparability - Accepted B.II.a.3.b Other excipients - B.II.a.3.b.3 Change that relates to a biological/immunological product - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Deletion of one manufacturing process of the active substance manufacturing processes -   |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000309498 | This was an application for a group of variations. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.c Deletion of a non-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27/11/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | significant in-process test - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted                                                                                                                                                                                                              |            |     |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| Variation type II / EMA/VR/0000284838 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final report from study ARGX-113-2002 and the accompanying bioanalytical reports. This is a long-term, single-arm, open-label, multicenter phase 3 study to evaluate the safety and tolerability of multiple subcutaneous injections of efgartigimod PH20 SC in patients with generalized myasthenia gravis (gMG). | 18/09/2025 | N/A | n/a |
| Variation type IB / EMA/VR/0000286181 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in                                                                                                                                                                                                                                                                                                                                                              | 30/07/2025 | N/A |     |

<div style=\"page-break-after: always\"></div>

|                                          | the manufacturing process - Accepted                                                                                                                                           |            |     |             |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA_IN / EMA/VR/0000266195 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted | 17/04/2025 | N/A |             |
| PSUR / EMA/PSUR/0000257895               | - -                                                                                                                                                                            |            |     | Maintenance |